Phase II study of nilotinib plus pegylated interferon alfa-2b as first-line therapy in chronic phase chronic myeloid leukaemia aiming to maximize complete molecular response and major molecular response (CML11)
收藏数据链接：
官方服务：
资源简介：
HeSANDA 1.0.0
创建时间：
2023-06-08
